As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to ...
Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer ...
The Big Pharma is paying up to $1.5 billion, split between an upfront fee and a milestone payment, to buy shingles vaccine ...
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug ...
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing ...
As the FDA adjusts to life without Marty Makary, M.D., Fierce has learned that the numerous policy reforms he put in motion ...
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...
One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin ...
Though the results show competitive efficacy and tolerability, they may leave some observers slightly underwhelmed based on ...
Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...
Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. | Cancer immunotherapy company Liminatus Pharma has agreed to pay out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results